What does this article add?
To our knowledge, it is the first real-world multi-center study in China
to demonstrate the real world effectiveness of initiated with PCSK-9
inhibitors combined with statins therapy among patients on very-high
risk ASVD and underwent PCI.
We found that patients received PCSK-9 inhibitor therapy had a
significant LDL-c reduction by about 50% patients reached ≤1.4mmol/L
goal and reduced 76% risk of cardiovascular events, compared to those
with statins during the 6 months follow-up period.